石药集团新药普卢格列汀片获批上市
财中社1月13日电石药集团（01093）发布公告，本集团开发的化学药品1类新药普卢格列汀片（商品名:善泽平）已获国家药品监督管理局批准上市。该产品为一种新型口服二肽基肽酶-IV（DPP-4）抑制剂，具有高选择性和强抑制性，能够有效降低血糖水平，适用于改善成人2型糖尿病患者的血糖控制。
支持该产品获批的两项关键Ⅲ期临床试验结果显示，其具有持久的降糖作用且不易诱发低血糖和增加体重。此外，该产品的不良反应发生率及与其他药物的相互作用可能性较低，轻中度肾功能不全患者在服用时无需调整剂量。该产品的获批将为2型糖尿病患者提供新的治疗选择，并进一步丰富公司的代谢疾病产品线。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10